{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:38:10Z","timestamp":1793252290946,"version":"4.5.0"},"reference-count":21,"publisher":"BMJ","issue":"4","funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","award":["Ashworth \/ Grant G00423"],"award-info":[{"award-number":["Ashworth \/ Grant G00423"]}],"id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Mucopolysaccharidoses (MPSs)\u00a0are a heterogeneous group of lysosomal storage disorders. Ocular complications (such as corneal clouding, retinopathy and optic neuropathy) are common. Notably, there is a paucity of data on the effect of genotype and systemic treatments (enzyme replacement therapy or haematopoietic stem cell transplantation) on the ocular phenotype in MPS. We prospectively studied the ocular features of patients with MPSI (Hurler\/Hurler-Scheie\/Scheie), MPSIV (Morquio) and MPSVI (Maroteaux-Lamy), to evaluate the effect of different therapeutic interventions and to correlate the findings with genetic and biomarker data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Prospective observational cohort study. Study participants underwent detailed ocular examination including visual acuity; assessment of corneal clouding (Iris camera Corneal Opacification Measure score and Pentacam densitometry) and retinal and optic nerve imaging (optical coherence tomography and wide-field fundus imaging). Data on genotype, biomarkers and delivered therapies (type and length of treatment) were also collected for each patient where available.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 21 patients with\u00a0MPSI, 4 patients with\u00a0MPSIV and 3 patients with\u00a0MPSVI were recruited. Corneal clouding scores were higher in MPSI compared with MPSIV and MPSVI. Retinopathy was evident in patients with\u00a0MPSI only. Association was observed between corneal clouding and biomarkers in MPSI, MPSIV and MPSVI. However, no clear association was seen between genotype or treatment type and ocular phenotype.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The ocular phenotype in MPS is variable, with corneal clouding occurring in MPSI, MPSIV and MPSVI, and retinopathy in MPSI only. There was an association between corneal clouding and efficacy of systemic treatment as measured by biomarkers.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjophthalmol-2017-311749","type":"journal-article","created":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T16:15:21Z","timestamp":1534522521000},"page":"504-510","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":22,"title":["Variability in the ocular phenotype in mucopolysaccharidosis"],"prefix":"10.1136","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8308-5377","authenticated-orcid":false,"given":"Krishanthy","family":"Sornalingam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Javed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Aslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Sergouniotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arunabha","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Ashworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,8,17]]},"reference":[{"key":"2023050800351116000_103.4.504.1","doi-asserted-by":"crossref","first-page":"v4","DOI":"10.1093\/rheumatology\/ker394","article-title":"Overview of the mucopolysaccharidoses","volume":"50 Suppl 5","author":"Muenzer","year":"2011","journal-title":"Rheumatology"},{"key":"2023050800351116000_103.4.504.2","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.2147\/OPTH.S78368","article-title":"Ocular manifestations and management recommendations of lysosomal storage disorders I: mucopolysaccharidoses","volume":"9","author":"Fenzl","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"2023050800351116000_103.4.504.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2005.11.007"},{"key":"2023050800351116000_103.4.504.4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6701921"},{"key":"2023050800351116000_103.4.504.5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ymgme.2017.12.434","article-title":"Gene therapy for Mucopolysaccharidoses","volume":"123","author":"Sawamoto","year":"2018","journal-title":"Mol Genet Metab"},{"key":"2023050800351116000_103.4.504.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2008.11.005"},{"key":"2023050800351116000_103.4.504.7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ymgme.2014.10.012","article-title":"Biomarker responses correlate with antibody status in mucopolysaccharidosis type I patients on long-term enzyme replacement therapy","volume":"114","author":"Langereis","year":"2015","journal-title":"Mol Genet Metab"},{"key":"2023050800351116000_103.4.504.8","first-page":"S8","article-title":"Serum HCII-T and urinary DS:CS ratio are both predictive biomarkers of treatment outcome in patients with MPS I, II and VI","volume":"102","author":"Bigger","year":"2011","journal-title":"Mol Genet Metab"},{"key":"2023050800351116000_103.4.504.9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-608075"},{"key":"2023050800351116000_103.4.504.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2010.02366.x"},{"key":"2023050800351116000_103.4.504.11","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1080\/13543784.2017.1397130","article-title":"Phase I and II clinical trials for the mucopolysaccharidoses","volume":"26","author":"Poswar","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"2023050800351116000_103.4.504.12","doi-asserted-by":"crossref","unstructured":"Javed A , Aslam T , Ashworth J . Use of new imaging in detecting and monitoring ocular manifestations of the mucopolysaccharidoses. Acta Ophthalmol 2016;94:e676-e682.doi:10.1111\/aos.13098","DOI":"10.1111\/aos.13098"},{"key":"2023050800351116000_103.4.504.13","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2011-300996"},{"key":"2023050800351116000_103.4.504.14","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2012-302913"},{"key":"2023050800351116000_103.4.504.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2011.02280.x"},{"key":"2023050800351116000_103.4.504.16","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/eye.2009.76","article-title":"Correlation in foveal thickness measurements between spectral-domain and time-domain optical coherence tomography in normal individuals","volume":"24","author":"Carpineto","year":"2010","journal-title":"Eye"},{"key":"2023050800351116000_103.4.504.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2012.08.010"},{"key":"2023050800351116000_103.4.504.18","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1007\/s00417-015-2953-y","article-title":"Spectral domain optical coherence tomography imaging of mucopolysaccharidoses I, II, and VI A","volume":"253","author":"Seok","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2023050800351116000_103.4.504.19","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00417-015-3058-3","article-title":"Spectral domain optical coherence tomography imaging of mucopolysaccharidoses I, II, IV A, and VI","volume":"253","author":"Lee","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2023050800351116000_103.4.504.20","doi-asserted-by":"crossref","unstructured":"Javed A , Aslam T , Jones SA , et al . The effect of haemopoietic stem cell transplantation on the ocular phenotype in mucopolysaccharidosis type I (Hurler). Acta Ophthalmol 2017. Advanced online publication. DOI.doi:10.1111\/aos.13627","DOI":"10.1111\/aos.13627"},{"key":"2023050800351116000_103.4.504.21","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1167\/iovs.16-20647","article-title":"Objective Quantification of Changes in Corneal Clouding Over Time in Patients With Mucopolysaccharidosis","volume":"58","author":"Javed","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2017-311749","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T07:37:18Z","timestamp":1683531438000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2017-311749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,17]]},"references-count":21,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,3,22]]},"published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1136\/bjophthalmol-2017-311749"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2017-311749","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,17]]}}}